| Literature DB >> 35355711 |
Si-Wei Rao1, Yuan-Yuan Duan1, Han-Qing Pang2, Shao-Hua Xu1, Shou-Qian Hu1, Ke-Guang Cheng1, Dong Liang1, Wei Shi1.
Abstract
Zanthoxylum nitidum (Roxb.) DC. (ZN), with strong effects of anti-inflammation and antioxidant activities is treated as a core herb in traditional Chinese medicine (TCM) preparation for treating stomachache, toothache, and rheumatoid arthritis. However, the active ingredients of ZN are not fully clarified due to its chemical complexity. In the present study, a double spectrum-effect analysis strategy was developed and applied to explore the bioactive components in herbs, and ZN was used as an example. Here, the chemical components in ZN were rapidly and comprehensively profiled based on the mass defect filtering-based structure classification (MDFSC) and diagnostic fragment-ion-based extension approaches. Furthermore, the fingerprints of 20 batches of ZN samples were analyzed by high-performance liquid chromatography, and the anti-inflammatory and antioxidant activities of the 20 batches of ZN samples were studied. Finally, the partial least squares regression (PLSR), gray relational analysis models, and Spearman's rank correlation coefficient (SRCC) were applied to discover the bioactive compounds in ZN. As a result, a total of 48 compounds were identified or tentatively characterized in ZN, including 35 alkaloids, seven coumarins, three phenolic acids, two flavonoids, and one lignan. The results achieved by three prediction models indicated that peaks 4, 12, and 17 were the potential anti-inflammatory compounds in ZN, whereas peaks 3, 5, 7, 12, and 13 were involved in the antioxidant activity. Among them, peaks 4, 5, 7, and 12 were identified as nitidine, chelerythrine, hesperidin, and oxynitidine by comparison with the standards and other references. The data in the current study achieved by double spectrum-effect analysis strategy had great importance to improve the quality standardization of ZN, and the method might be an efficiency tool for the discovery of active components in a complex system, such as TCMs.Entities:
Keywords: Zanthoxylum nitidum (Roxb.) DC.; anti-inflammation; antioxidant activity; chemical profiling; spectrum–effect relationship
Year: 2022 PMID: 35355711 PMCID: PMC8959880 DOI: 10.3389/fphar.2022.794277
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1The strategy for discovering bioactive markers in Zanthoxylum nitidum (Roxb.) DC. (ZN) by ultrahigh-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC Q-TOF MS) coupled with comprehensive filtering approaches.
FIGURE 2The structure-diagnostic ion-oriented network (A). The mass defect ranges of different types of alkaloids in ZN (B); the correlations between the mass ranges and mass shifts of the basic skeletons of ZN alkaloids (C). MDFSC, mass defect filtering-based structure classification; DFIBE, diagnostic fragment-ion-based extension.
Characterization of chemical constituents of Zanthoxylum nitidum (Roxb.) DC. (ZN) sample.
| No. | TR (min) | Identification | Formula | Theoretical mass ( | Measured mass ( | Error (ppm) | In mode | MS/MS ( |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.32 | L-Arginine | C6H14N4O2 | 175.1190 | 175.1194 | −2.28 | [M+H]+ | 158.0901, 144.1377, 130.0963, 116.0705, 100.0756 |
| 2 | 1.32 | (E)-3-(3,4,5-trihydroxyphenyl) acrylaldehyde | C9H8O4 | 181.0495 | 181.0492 | 1.66 | [M+H]+ | 153.0539, 140.0461, 125.0589, 110.0353 |
| 3 | 1.90 | Chlorogenic acid | C16H18O9 | 355.1024 | 355.1036 | −3.38 | [M+H]+ | 266.0805, 193.0491, 163.0387, 135.0439, 117.0331 |
| 4 | 2.13 | Magnocurarine A | C19H24NO3 + | 314.1756 | 314.1754 | 0.64 | [M]+ | 269.1164, 237.0899, 175.0747, 107.0482 |
| 5 | 2.38 | Magnoflorine A | C20H24NO4 + | 342.1705 | 342.1709 | −1.46 | [M]+ | 297.1124, 282.0891, 237.0911, 222.0678, 192.1021 |
| 6 | 3.14 | Magnocurarine B | C19H24NO3 + | 314.1756 | 314.1771 | −4.77 | [M]+ | 314.1760, 269.1174, 237.0909, 175.0751, 107.0489 |
| 7 | 3.20 | 3′-hydroxy-4′,6,7-trimethoxyl-N,N-dimethyltetrahydroisoquinoline | C21H28NO4 + | 358.2018 | 358.2024 | −1.68 | [M]+ | 298.1196, 267.1011, 206.1171, 174.0617, 137.0594 |
| 8 | 3.42 | D-Tertrahydropaimatine | C21H25NO4 | 356.1869 | 356.1856 | −3.65 | [M+H]+ | 192.1022, 177.0785, 137.0594 |
| 9 | 3.59 | (Z)-3-(2-(2-hydroxypropan-2-yl)-2,3-dihydrobenzofuran-5-yl) acrylic acid | C14H16O4 | 249.1130 | 249.1121 | 3.61 | [M+H]+ | 203.0703, 189.0548, 171.0437, 161.0590, 141.0694, 129.0695, 115.0538 |
| 10 | 4.00 | Dimethyl 5-[(6-phenethylpyridin-3-yl) methyl] isophthalate | C24H23NO4 | 390.1574 | 390.1559 | 3.84 | [M+H]+ | 330.0732, 295.0600, 254.0576, 209.0593, 167.0488 |
| 11 | 4.18 | Protopine | C20H19NO5 | 354.1336 | 354.1349 | −3.67 | [M+H]+ | 320.0918, 247.0750, 192.1021, 149.0594, 107.0485 |
| 12 | 4.34 | Analog of liriodenine | C19H17NO4 | 324.1241 | 324.1230 | 3.39 | [M+H]+ | 309.0998, 281.1047, 266.0812, 192.1021, 177.0786, 145.0282, 117.0333 |
| 13 | 4.40 | Tertrahydropaimatine | C21H25NO4 | 356.1869 | 356.1856 | 3.65 | [M+H]+ | 340.1544, 192.1021, 177.0786, 145.0282 |
| 14 | 4.49 | Analog of oxyavicine | C21H21NO5 | 368.1492 | 368.1498 | −1.63 | [M+H]+ | 352.1191, 324.1240, 310.1082, 292.0970, 264.0662, 204.0654 |
| 15 | 4.62 | Magnoflorine B | C20H24NO4 + | 342.1705 | 342.1710 | −1.17 | [M]+ | 297.1123, 282.0886, 237.0906, 222.0672, 207.0801 |
| 16 | 5.16 | Palmatrubin | C20H19NO4 | 338.1387 | 338.1401 | −4.14 | [M+H]+ | 307.0841, 265.0735, 237.0783, 190.0863, 175.0628 |
| 17 | 5.19 | Allocryptopine | C21H23NO5 | 370.1649 | 370.1657 | −2.16 | [M+H]+ | 336.1223, 290.0932, 252.0774, 206.0802, 188.0698, 149.0591 |
| 18 | 5.21 | 10-Methoxy-2,3-dihydro-7H-[1,4] dioxino[2,3-g] chromen-7-one | C12H10O5 | 235.0601 | 235.0607 | −2.55 | [M+H]+ | 205.0497, 191.0341, 177.0547, 163.0389, 149.0230, 135.0441, 121.0283, 107.0488 |
| 19 | 5.47 | Jatrorrhizine | C20H19NO4 | 338.1400 | 338.1391 | 2.66 | [M+H]+ | 322.1091, 294.1130, 280.0972, 265.0733, 222.0914 |
| 20 | 5.62 | Diosmin | C28H32O15 | 609.1814 | 609.1815 | −0.16 | [M+H]+ | 463.1234, 301.0706, 285.0753, 263.0551, 245.0445, 177.0551 |
| 21 | 5.86 | Hesperidin | C28H34O15 | 611.1970 | 611.1995 | −4.09 | [M+H]+ | 465.1351, 303.0872, 285.0754, 263.0553, 245.0448, 177.0550 |
| 22 | 6.35 | Haplopine | C13H11NO4 | 246.0761 | 246.0768 | −2.84 | [M+H]+ | 231.0526, 216.0289, 188.0343, 160.0390 |
| 23 | 6.37 | Isofagaridine | C20H16NO4 + | 344.1079 | 344.1069 | 2.91 | [M]+ | 319.0849, 291.0897, 276.0663, 262.0865 |
| 24 | 6.60 | Palmatine | C21H22NO4 | 352.1543 | 352.1555 | −3.41 | [M+H]+ | 336.1236, 320.1285, 292.0972, 190.0859 |
| 25 | 6.71 | Sanguinarine A | C20H14NO4 + | 332.0917 | 332.0932 | −4.52 | [M]+ | 319.0842, 291.0892, 274.0870, 246.0915, 216.0808 |
| 26 | 6.77 | Epiberberine | C20H17NO4 | 336.1230 | 336.1242 | −3.57 | [M+H]+ | 320.0919. 304.0968, 292.0970, 278.0814, 263.0936 |
| 27 | 7.16 | Sanguinarine B | C20H14NO4 + | 332.0917 | 332.0934 | −5.12 | [M]+ | 319.0843, 291.0890, 274.0866, 246.0914, 216.0806 |
| 28 | 8.06 | Marmesin | C14H12O4 | 245.0808 | 245.0813 | −2.04 | [M+H]+ | 212.0460, 191.0337, 163.0387, 147.0436, 128.0616 |
| 29 | 8.32 | Nitidine A | C21H18NO4 + | 348.1230 | 348.1246 | −4.60 | [M]+ | 332.0926, 318.0763, 304.0974, 290.0818, 275.0939 |
| 30 | 8.71 | Chelerythrine | C21H17NO4 | 348.1230 | 348.1240 | −2.87 | [M+H]+ | 332.0921, 318.0759, 304.0968, 290.0812 |
| 31 | 9.31 | γ-Fagarine | C13H11NO3 | 230.0812 | 230.0821 | −3.91 | [M+H]+ | 215.0580, 200.0340, 186.0547, 172.0394, 158.0600 |
| 32 | 9.63 | Skimmianine | C14H13NO4 | 260.0917 | 260.0925 | −3.08 | [M+H]+ | 227.0574, 200.0661, 199.0629, 184.0390, 170.0593 |
| 33 | 9.83 | 5-Methoxydictamnine | C13H11NO3 | 230.0812 | 230.0819 | −3.04 | [M+H]+ | 215.0579, 200.0340, 186.0547, 172.0398, 158.0594 |
| 34 | 9.86 | Dictamnine | C12H9NO2 | 200.0706 | 200.0715 | −4.50 | [M+H]+ | 185.0474, 156.0446, 129.0576, 102.0466 |
| 35 | 10.16 | Nitidine B | C21H18NO4 + | 348.1230 | 348.1240 | −2.87 | [M]+ | 332.0922, 318.0763, 304.0969, 290.0813, 275.0937 |
| 36 | 10.90 | Unknown | C15H14O5 | 275.0914 | 275.0918 | −1.45 | [M+H]+ | 229.0493, 217.0497, 203.0338, 175.0390, 161.0596 |
| 37 | 12.03 | Analog of magnoflorine | C36H42NO9 + | 632.2875 | 632.2870 | 0.79 | [M]+ | 342.1700, 297.1124, 282.0890, 265.0862, 237.0912, 222.0673, 191.0852 |
| 38 | 15.13 | Toddanone | C16H18O5 | 291.1227 | 291.1236 | −3.09 | [M+H]+ | 219.0652, 205.0496, 191.0702, 161.0597, 131.0488 |
| 39 | 16.42 | Analog of jatrorrhizine | C27H41NO13 | 610.2470 | 610.2448 | 3.61 | [M+Na]+ | 338.1390, 322.1077, 294.1123, 280.0973, 190.0862, 161.0595, 105.0700 |
| 40 | 16.79 | Analog of nitidine | C28H31NO6 + | 477.2151 | 477.2150 | 0.21 | [M]+ | 348.1234, 332.0927, 318.0769, 304.0975, 290.0818, 275.0936 |
| 41 | 18.46 | Oxynitidine | C21H17NO5 | 364.1179 | 364.1192 | −3.57 | [M+H]+ | 348.0867, 334.0716, 320.0919, 306.0766, 290.0455, 278.0809 |
| 42 | 18.77 | 5,7-Dimethoxy-8-(3-methyl-2-butenoxy) coumarin | C16H18O5 | 291.1227 | 291.1233 | −2.06 | [M+H]+ | 220.0366, 193.0134, 178.0259, 165.0184, 133.0284, 107.0486 |
| 43 | 19.49 | 6-Ethoxychelerythrine | C23H23NO5 | 394.1654 | 394.1666 | −3.04 | [M+H]+ | 376.1548, 361.1313, 346.1093, 318.1125, 330.1127, 288.0795, 260.0829 |
| 44 | 20.16 | Phellopterin | C17H16O5 | 301.1071 | 301.1081 | −3.32 | [M+H]+ | 218.0210, 190.0255, 162.0309, 134.0361, 106.0409 |
| 45 | 21.54 | Suberosin | C15H16O3 | 245.1172 | 245.1181 | −3.67 | [M+H]+ | 215.0698, 187.0389, 175.0389, 143.0488, 131.0488 |
| 46 | 23.25 | Dihydronitidine | C21H19NO4 | 350.1387 | 350.1399 | −3.43 | [M+H]+ | 334.1078, 319.0838, 290.0816, 247.0759, 219.0805 |
| 47 | 23.64 | Dihydrochelerythrine | C21H19NO4 | 350.1387 | 350.1385 | 0.53 | [M+H]+ | 334.1085, 319.0848, 290.0821, 247.0756, 219.0804 |
| 48 | 25.67 | Analog of nitidine | C36H32NO9 + | 622.2072 | 622.2090 | −2.89 | [M]+ | 348.1230, 332.0920, 318.0760, 304.0969, 290.0814, 246.0912 |
FIGURE 3Tentative fragmentation pathway and mass spectrogram of several typical alkaloids in ZN. (A,B) Skimmianine; (C,D) jatrorrhizine; (E,F) magnoflorine.
FIGURE 4HPLC fingerprints and common peaks of 20 batches of ZN samples (A). Cluster analysis of 20 batches of ZN samples (B).
FIGURE 5The NO inhibition and the antioxidant activities of 20 batches of ZN samples. (A) NO inhibition; (B) DPPH. Values represent means ± SD, n = 5 (A); n = 3 (B).
FIGURE 6The three pharmacodynamic models to discover principal bioactive components. The results of partial least squares regression (PLSR, A–F): the loading scatters of PLSR (A: anti-inflammatory; D: antioxidant, colored according to density); regression coefficient between the 18 common peaks and the anti-inflammatory, antioxidant activities, respectively (B: anti-inflammatory; E: antioxidant), and VIP values (C: anti-inflammatory; F: antioxidant). The heat map of bioactivities of 18 compounds by GRA analysis (G) and Spearman's rank correlation coefficient (SRCC) (H) in ZN samples. Peaks 1–18 represent the common peaks.